Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Test for better prevention of cervical cancer receives FDA approval

No. 26c | 30/04/2020 | by Koh

Women infected with high-risk types of human papillomavirus (HPV) have a high risk of developing cervical cancer. A test can help doctors to better assess this risk and identify those women who should be referred immediately for further diagnostic investigation. The test has now been approved by the US Food and Drug Administration (FDA) and will soon be widely available to doctors and patients. The test was developed by mtm Laboratories AG, a spin-off from the German Cancer Research Center and the University Hospital in Heidelberg, which was acquired by Roche in 2011.

Tissue section from the cervix: The brown color is an indication of malignant cells.
© mtm laboratories

In 1999, scientists led by Magnus von Knebel Doeberitz from the German Cancer Research Center (DKFZ) and the University Hospital of Heidelberg founded mtm laboratories ("molecular tools in medicine") with the aim of developing the detection of the cancer protein p16 as a diagnostic test for the early detection of cervical cancer. The company was one of the first spin-offs in which the DKFZ held shares.

The company developed the test and launched it under the name CINtec PLUS. The immunohistological method detects the simultaneous presence of the two biomarkers p16 and Ki-67 in a single cell. A positive result indicates that an HPV-infected woman has already developed a precancerous stage that requires immediate clinical clarification. HPV-positive women, on the other hand, in whom the test is negative, have not developed a precancerous stage, so further screening intervals can be significantly extended.

In 2011, mtm laboratories was acquired by Roche, a leading international provider of diagnostics and therapeutics. Roche has now received US FDA (Food and Drug Administration) approval for CINtec PLUS to help clinicians improve cervical cancer prevention. FDA approvals are based on very extensive studies involving many thousands of participants. To date, there are only a few examples of products from German biotech companies that have made it this far. It is expected that the test will be commercially available on a broad basis in the USA in the course of 2020.

CINtec PLUS cytology provides crucial information on which HPV-positive women can benefit most from an immediate referral to colposcopy. This is an important step to individualize patient care and prevent both over- and under-treatment.

Rainer Wessel, Chief Innovation Officer at the DKFZ, calls the development from the idea to a marketable test kit an "exemplary success story". "Thanks to the initiative of the company founders led by Magnus von Knebel Doeberitz, an important cancer test will soon be available worldwide because FDA approvals usually have a signal character for the approval authorities of other countries. This example shows that spin-offs are an excellent opportunity to further develop promising inventions from basic research into medical products. The DKFZ supports inventors in all phases of this process."

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS